Teva’s Barr Labs settles Cipro antitrust case for $225 mln

1 Attorneys

#1 Attorneys Network

1 Legal - 1 Lawyers - 1 Attorneys

Injury Lawyer - Criminal - Foreclosure - Divorce

 

By Komal Khettry

<span class="articleLocation”>Teva Pharmaceutical Industries Ltd’s
Barr Laboratories Inc has reached a $225 million settlement in
an antitrust class action that accused the drugmaker of keeping
a generic version of Bayer AG’s antibiotic Cipro off
the market, court documents showed.

The case, which began in 2000 in California state court,
centers on a series of settlements in the late 1990s under which
Bayer allegedly paid Barr Pharmaceuticals, since bought by Teva,
$398 million not to market Cipro’s generic version. Bayer had
earlier sued Barr claiming that generic Cipro would infringe a
Bayer patent. reut.rs/2jkzNtL

The plaintiffs, a group of non-profits and individuals in
California who bought Cipro, claimed that the settlement drove
up the price of the drug and violated California’s antitrust law
and the Cartwright Act.

In December, Teva Pharmaceutical agreed to pay more than
$519 million to settle U.S. criminal and civil allegations that
the company bribed overseas officials to gain business for its
medications.

The settlement requires an approval from California’s
highest court.



1 Attorneys
1 Attorneys

1 Legal

#1 Attorneys Search Engine

1 Legal is part of the 1 Search Project

Practice Areas - News - Federal - State - Contact Us


Facebooktwitterredditpinterestlinkedinmail

Facebooktwitterlinkedinrss

1 Attorneys

#1 Attorneys Network

1 Legal - 1 Lawyers - 1 Attorneys

Injury Lawyer - Criminal - Foreclosure - Divorce

 


Leave a Reply